Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: A meta-analysis

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2579-2588

  Crucitti, Antonio ^a   Zhang, Qi ^b   Nilsson, Mary ^b   Brecht, Stephan ^c   Yang, Charles R ^d   Wernicke, Joachim ^b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b ELI LILLY AND COMPANY   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d Shanghai ChemPartner Co Ltd   (China)

Author keywords

Diabetes; Diabetic peripheral neuropathic pain; Duloxetine; Fasting plasma glucose; HbA1c; SNRI

Indexed keywords

DULOXETINE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO;

ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; DIABETIC NEUROPATHY; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LOW BACK PAIN; MAJOR DEPRESSION; META ANALYSIS; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BLOOD GLUCOSE; DIABETIC NEUROPATHIES; FEMALE; GLYCEMIC INDEX; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MOOD DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TREATMENT OUTCOME;

EID: 77958146417     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003769241     Document Type: Article

References (37)

1. Grigsby AB, Anderson RJ, Freedland KE, et al. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 2002;53:1053-60
2. Lin EH, Korff MV, Alonso J, et al. Mental disorders among persons with diabetes-results from the World Mental Health Surveys. J Psychosom Res 2008;65:571-80
3. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Safety 2006;5:157-68
4. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "Metabolic Syndrome Type II"? Ann Clin Psychiatry 2007;19:257-64
5. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-42
6. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54:317-29
7. Ciechanowski PS, Katon WJ, Russo JE, et al. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 2003;25:246-52
8. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-78
9. Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med 2008;121(11 Suppl 2):S8-15
10. Derijks HJ, Heerdink ER, De Koning FH, et al. The association between anti-depressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiol Drug Saf 2008;17:336-44
11. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008;24(Suppl 1):S52-7
12. Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complicat 2008;22:241-5
13. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22:417-42
14. Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007;30:21-6
15. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-74
16. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9:100-7
17. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titra-tion, placebo-controlled trial. Depress Anxiety 2008;25:182-89
18. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009;39:267-76
19. Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibro-myalgia. Int J Gen Med 2009;1:91-102
20. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
21. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-8
22. Skljarevski V, Zhang S, Chappell AS, et al. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med 2010;11:648-57
23. Perahia DG, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-16
24. American Diabetes Association. Standards of medical care in diabetes\-2010. Diabetes Care 2010;33(Suppl 1):S11-S61
25. Wentworth JM, Fourlanos S, Harrison LC. Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nat Rev Endocrinol 2009;5:483-9
26. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials 1986; 7:267-75
27. Osterman-Golkar SM, Vesper HW. Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complicat 2006;20:285-94
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
29. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998;280:1490-6
30. Mazze RS, Lucido D, Shamoon H. Psychological and social correlates of glycemic control. Diabetes Care 1984;7:360-6
31. Fisher L, Skaff MM, Mullan JT, et al. A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with type 2 diabetes. Diabet Med 2008;25:1096-101
32. Kroke A, Liese AD, Keil U, et al. Arterial hypertension and glycemia in non-diabetic subjects: is there an association independent of obesity? Diabetes Metab Res Rev 1999;15:99-105
33. Sathiyapriya V, Selvaraj N, Nandeesha H, et al. Enhanced glycation of hemoglobin and plasma proteins is associated with increased lipid peroxide levels in non-diabetic hypertensive subjects. Arch Med Res 2007;38:822-6
34. Selvin E, Zhu H, Brancati FL. Elevated A1C in adults without a history of diabetes in the U.S. Diabetes Care 2009;32:828-33
35. McTigue KM, Hess R, Ziouras J. Obesity in older adults: a systematic review of the evidence for diagnosis and treatment. Obesity (Silver Spring) 2006;14:1485-97
36. Lyssenko V, Almgren P, Anevski D, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005;54:166-74
37. Looker HC, Knowler WC, Hanson RL. Changes in BMI and weight before and after the development of type 2 diabetes. Diabetes Care 2001;24:1917-22